James C. Mullen's investment activity in Biogen has shown interesting trends over the years. By the end of 2022, his insider trading reflected values consistently around $6-8 million monthly prior to his tenure at Editas and showed a notable peak...

James C. Mullen's investment activity in Biogen has shown interesting trends over the years. By the end of 2022, his insider trading reflected values consistently around $6-8 million monthly prior to his tenure at Editas and showed a notable peak during late 2021, reaching almost $9.5 million in monthly values. This demonstrates the fluctuations in his investments, aligning with significant company events and performance metrics. Prior to that peak, his investments maintained strong numbers, often exceeding $6 million monthly throughout 2020 and into 2021. His trading patterns indicate an alignment with company performance and a strategic approach to managing his financial interests as a leader in the biotech space.